ARQ 736

Drug Profile

ARQ 736

Alternative Names: ARQ-736

Latest Information Update: 04 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule
  • Class Antineoplastics; Imidazoles; Oxazoles; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Mar 2014 Discontinued - Phase-I for Solid tumours (late-stage disease) in Italy before March 2014 (Oral)
  • 31 Mar 2014 Discontinued - Phase-I for Solid tumours (late-stage disease) in USA before March 2014 (Oral)
  • 01 Mar 2013 ArQule completes a phase I trial for Solid tumours (late-stage disease) in USA and Italy (NCT01225536)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top